SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (18873)4/8/1998 8:28:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
ML has a fairly new Biotech analyst. He probably let everyone know the direction of chemoprevention, so they downgraded ZEN in preparation for re-initiation of coverage of LGND :-).



To: Wallace Rivers who wrote (18873)4/8/1998 8:31:00 AM
From: Henry Niman  Respond to of 32384
 
Dow Jones Newswires -- April 8, 1998
Merrill Lynch Cuts Zeneca To Neutral From Accumulate

LONDON (Dow Jones)--Merrill Lynch cut its recommendation
Wednesday on Zeneca Group PLC (ZEN) to 'neutral' from 'accumulate.'

Around 1055 GMT, shares in Zeneca are down 34 pence at 2722 pence.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News